Cargando…

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro

Detalles Bibliográficos
Autores principales:	Wei, Qilu, Kong, Ning, Liu, Xiaohui, Tian, Run, Jiao, Ming, Li, Yiyang, Guan, Huanshuai, Wang, Kunzheng, Yang, Pei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522190/ https://www.ncbi.nlm.nih.gov/pubmed/34663335 http://dx.doi.org/10.1186/s12967-021-03106-8

Ejemplares similares

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Melatonin increases bone mass in normal, perimenopausal, and postmenopausal osteoporotic rats via the promotion of osteogenesis
por: Guan, Huanshuai, et al.
Publicado: (2022)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

An injectable self-adaptive polymer as a drug carrier for the treatment of nontraumatic early-stage osteonecrosis of the femoral head
por: Kong, Ning, et al.
Publicado: (2022)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents
por: Gu, Chenxi, et al.
Publicado: (2022)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

Prediction of early functional outcomes in patients after robotic-assisted total knee arthroplasty: a nomogram prediction model
por: Duan, Xudong, et al.
Publicado: (2023)

Learning curve and short-term clinical outcomes of a new seven-axis robot-assisted total knee arthroplasty system: a propensity score-matched retrospective cohort study
por: Duan, Xudong, et al.
Publicado: (2023)

Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2
por: Antar, Samar A., et al.
Publicado: (2022)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis
por: Gan, Donghao, et al.
Publicado: (2021)

Synovial Fibrosis Involvement in Osteoarthritis
por: Zhang, Li, et al.
Publicado: (2021)

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
por: Ishii, Kenichiro, et al.
Publicado: (2019)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment
por: Brandli, Alice, et al.
Publicado: (2022)

Osteogenesis-Related Long Noncoding RNA GAS5 as a Novel Biomarker for Osteonecrosis of Femoral Head
por: Liu, Guanzhi, et al.
Publicado: (2022)

Fibrotic microtissue array to predict anti-fibrosis drug efficacy
por: Asmani, Mohammadnabi, et al.
Publicado: (2018)

Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
por: Costalonga, Elerson C., et al.
Publicado: (2017)

Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy
por: Zhang, Zequn, et al.
Publicado: (2021)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis
por: Cicko, Sanja, et al.
Publicado: (2015)

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
por: Cilli, Aykut, et al.
Publicado: (2023)

Novel Anti-fibrotic Therapies
por: McVicker, Benita L., et al.
Publicado: (2017)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
por: Sato, Seidai, et al.
Publicado: (2017)

Implementation of pre-clinical methodologies to study fibrosis and test anti-fibrotic therapy
por: Oakley, Fiona, et al.
Publicado: (2019)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9nmbhbg8bbr565ro2teoa5calm